Abstract:Sanling Shi, Shuting Kong, Weicheng Ni, Yucheng Lu, Junfeng Li, Yuheng Huang, Jinxin Chen, Ken Lin, Yuanmiao Li, Jiayu Ke, Hao Zhou Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China Correspondence: Hao Zhou, Email Background: The systemic immune-inflammation index (SII; neutrophil × platelet/lymphocyte) is a novel marker for immune and inflammatory status and is associated with adverse prognosis in cardiovascular disease. Methods: In total, 744 patients diagnosed with acute coronary syndrome (ACS) and chronic kidney disease (CKD) were included in our study, received standard therapies, and were followed up. Patients were divided into high and low SII groups according to the baseline SII. The primary endpoint was major cardiovascular events (MACEs), defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Results: During a median follow-up of 2.5 years, a total of 185 (24.9%) MACEs were recorded. Analysis of the ROC curve revealed that the best cutoff value of SII was 1159.84× 10 9 /L for predicting MACEs. The Kaplan–Meier analysis showed that those patients in the low SII group had higher survival rates than those in the high SII group (p < 0.001). Compared to those in the low SII group, patients in the high SII group were at significantly higher risk of MACEs (134 (38.8%) vs 51 (12.8%), p < 0.001). Univariate and multivariable Cox regression analyses revealed that a high SII level was independently associated with MACEs in ACS patients with CKD (adjusted hazard ratio [HR]: 1.865, 95% confidence interval [CI]: 1.197– 2.907, p = 0.006). Conclusion: The present study showed that an elevated SII is associated with adverse cardiovascular outcomes in ACS with CKD patients, suggesting that SII may be a valuable predictor of poor prognosis in ACS with CKD patients. Further studies are needed to confirm our findings. Keywords: acute coronary syndrome, chronic kidney disease, inflammation, prognosis Chronic kidney disease (CKD) is common in patients with cardiovascular disease; an estimated 30% to 40% of patients with myocardial infarction (MI) have CKD. 1 Indeed, CKD is an independent predictor for adverse cardiovascular events, further leading to poor clinical outcomes for patients. 2 Acute coronary syndrome (ACS) and CKD are related, making the condition more complicated. Creatinine showed a close association with cardiovascular events and several risk scores containing creatinine, such as PRECISION DAPT, ACEF, and SYNTAX II, have been developed to predict the occurrence of clinical outcomes. 3–5 However, patients with advanced CKD have been widely excluded from clinical trials in this area. Therefore, no standard regimen has been established for such patients, and there are limited data on outcomes in this patient population. Thus, it is necessary to explore more effective biomarkers and adjunctive therapeutic strategies to improve the prognosis of ACS patients with CKD. Vascular inflammation drives atherosclerotic plaque formation and destabilization and contributes to the progression of ACS. 6 Additionally, CKD is a chronic inflammatory disease involving many causes and inflammation may represent a marker of poor outcomes in CKD patients. 7 According to the findings of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial, anti-inflammatory medication effectively lowers the risk of major adverse cardiovascular events in CKD patients. 8,9 Studies have revealed a significant association between immunological and inflammatory responses and atherosclerosis development, and numerous biomarkers have been used as a predictors in coronary artery disease (CAD) patients. 10–12 The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) are significant inflammatory biomarkers that may be associated with atherosclerosis and predict various cardiovascular events. 13,14 Recently, Hu et al created a new inflammatory index, the systemic immune-inflammation index (SII; neutrophil × platelet/lymphocyte) to assess the inflammatory and immune status. 15 SII is associated with poor prognosis in individuals with several types of cancers, suggesting that SII may be a prognostic indicator in various malignant diseases. 15–17 Moreover, recent studies have shown that SII is strongly linked to adverse outcomes in patients with cardiovascular disease. 18,19 In addition, CKD has been considered a major risk factor for congestive heart failure (CHF), and the risk increases with the deterioration of renal function. 20 A study has shown that SII has predictive value for -Abstract Truncated-

Differences in the Profile of Circulating Immune Cell Subsets in Males with Type 2 Cardiorenal Syndrome versus CKD Patients without Established Cardiovascular Disease

The prevalence of type 2 cardio-renal syndrome in inpatients with chronic heart disease

P0297CHANGES OF CD4CD28NULL AND CD8CD28NULL T CELLS IN CHRONIC KIDNEY DISEASE AND THE IMPACT OF DIFFERENT DIALYSIS MODALITIES

Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease: results from a UK electronic health record database

Cardiorenal Syndrome in Incident Peritoneal Dialysis Patients: What is Its Effect on Patients' Outcomes?

Association of the Systemic Immune-Inflammation Index with Outcomes in Acute Coronary Syndrome Patients with Chronic Kidney Disease

Identification of Novel Independent Correlations between Cellular Components of the Immune System and Strain-Related Indices of Myocardial Dysfunction in CKD Patients and Kidney Transplant Recipients without Established Cardiovascular Disease

Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD

Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology.

Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD

Association of Monocyte Count and Monocyte/Lymphocyte Ratio with the Risk of Cardiovascular Outcomes in Patients with CKD

Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients With End-Stage Renal Disease

Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes

Red Blood Cell Distribution Width to Albumin Ratio for Predicting Type I Cardiorenal Syndrome in Patients with Acute Myocardial Infarction: A Retrospective Cohort Study

Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Chronic Kidney Disease-Associated Inflammation Increases the Risks of Acute Kidney Injury and Mortality after Cardiac Surgery

Exploring diagnostic biomarkers of type 2 cardio-renal syndrome based on secreted proteins and bioinformatics analysis

Cardio-renal syndromes in patients admitted with ST-elevation myocardial infarctions: Incidence and impact on renal and overall outcome

Associations of C-reactive protein-albumin-lymphocyte (CALLY) index with cardiorenal syndrome: Insights from a population-based study

NT-probnp Variability as a Predictor of Adverse Outcomes in Patients With Cardiorenal Syndrome Type 2

Comprehensive assessment of cardiovascular-kidney-metabolic (CKM) syndrome: Novel tools for assessment of cardiovascular risk and kidney outcomes in long-term kidney transplant patients